Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 20/20 | 0.94 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.94 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19861606 | 1.00 | CYP3A4 (0.94) | CYP3A4CYP2D6CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL2736224 | 0.97 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL22356526 | 0.97 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL2736330 | 0.97 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL2736095 | 0.97 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL19861711 | 0.93 | CYP3A4 (0.94) | CYP3A4CYP2D6CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL18532032 | 0.93 | CYP3A4 (0.83) | CYP3A4CYP2D6CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL19861607 | 0.92 | CYP3A4 (0.86) | CYP3A4CYP2D6CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL2736320 | 0.92 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL2736093 | 0.92 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C9CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170158647-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158647-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, SLC26A4 | CYP3A4 160/4885CYP2D6 105/4885CYP2C9 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.